Congrats to our client @formationbio on its new $600M #DrugDevelopment Accelerator Fund to expand its clinical-stage portfolio. The fund will in-license or acquire Phase 1/2 programs, each housed in its own entity and backed by Formation’s shared development platform.
Today we’re announcing the $600M Formation Bio Drug Development Accelerator Fund.
@lintaho and I started @FormationBio because we believed the biggest bottleneck in bringing new medicines to patients wasn’t drug discovery, but drug development.
As AI dramatically accelerates discovery, that bottleneck is only becoming more acute. Without the capital and capacity to advance promising drugs through clinical trials, much of that progress won’t translate into medicines for patients.
Our new Fund brings together dedicated capital, drug development expertise, and AI-powered development capabilities to acquire promising drugs and advance them through the clinic.View quoted post on X
